Posts by Alicia
How virtual reality is changing the game for Alzheimer’s disease
How virtual reality is transforming Alzheimer’s disease research Via The Cognitive Neuroscience Society October 30, 2025 How virtual reality is changing the game for Alzheimer’s disease For most people, putting on virtual reality (VR) goggles means entering a video game. But for Dr. Manu Madhav, a CLEAR-funded neuroscientist at the University of British Columbia, it’s…
Read MoreHealth Canada approves LEQEMBI™ the first Alzheimer’s treatment to target the underlying cause of the disease
Health Canada announces approveal of Alzheimer’s drug treatment LEQEMBI™ Via Biogen Canada October 27, 2025 A new era of hope for Canadians living with early Alzheimer’s disease For the first time, Canadians living with early Alzheimer’s disease have access to a treatment that targets the underlying cause of the condition. Health Canada has granted authorization with…
Read MoreCLEAR scientist Dr. Printha Wijesinghe explores tear-based microRNAs for early Alzheimer’s detection
CLEAR-funded scientist Dr. Printha Wijesinghe advances tear-based microRNA research for early Alzheimer’s disease. Via Djavad Mowafaghian Centre for Brain Health (DMCBH) October 24, 2025 CLEAR funded scientist advancing research for early Alzheimer’s diagnosis For Dr. Printha Wijesinghe, the road to neuroscience has been anything but ordinary. Born in Jaffna, Sri Lanka, amid civil war…
Read MoreAdvancing Alzheimer’s Research Through Collaboration: CLEAR Meets with BC Government Leaders
CLEAR Foundation meets with BC MLAs to Advocate for Alzheimer’s Research Investment in BC October 21, 2025 Uniting science and government action in the fight against dementia On October 9, CLEAR’s Executive Team and Board of Directors met with Members of the Legislative Assembly (MLAs) from both the BC NDP and BC Conservative caucuses…
Read More2025 Trainee Grant Funding Announcement
CLEAR Foundation announces the co-funding of two Health Research BC trainee recipients, the second made possible with the support of Acuitas Therapeutics. October 16, 2025 Supporting early-career scientists leading bold new approaches in dementia research. We are delighted to announce two CLEAR-funded researchers through Health Research BC’s 2025 partnered Trainee Awards. Thanks to the generosity…
Read MoreNew Alzheimer’s drugs offer hope for the future of dementia care
A new era of Alzheimer’s treatment brings hope for Canadian families Via CTV News October 13, 2025 Newly approved Alzheimer’s treatments brings optimism for Canadians Across Canada, families and researchers alike are encouraged by two groundbreaking Alzheimer’s therapies, lecanemab (Leqembi) and donanemab (Kisunla), that have shown strong results in slowing the progression of early-stage…
Read MoreNIH 2025 dementia research progress report: key advances
NIH 2025 dementia research project report: key advances Via The National Institute of Aging October 1, 2025 What the 2025 NIH Dementia Progress Report means for Alzheimer’s research The recently published 2025 NIH Alzheimer’s Disease and Related Dementias Research Progress Report highlights groundbreaking strides in prevention, diagnosis, treatment, and caregiving. Read the full report…
Read MoreCanada’s national dementia strategy: report insights
Canada’s national dementia strategy: Key report insights Based on The Government of Canada September 22, 2025 Canada’s commitment to dementia care and research In November 2024, The Public Health Agency of Canada released The 2024 Dementia Strategy for Canada: Together We Achieve report. This report provides an overview of the progress made since the national…
Read MoreGovernment of Canada announces $44.8 Million investment in dementia research
Government of Canada’s $44.8 million dementia funding announcement Via The Canadian Institutes of Health Research September 10, 2025 The Government of Canada’s $44.8M investment will fund dementia and brain health innovation. The Canadian Institutes of Health Research recently unveiled a transformative $44.8 million investment in dementia and healthy brain aging research, one of the most…
Read MoreFDA approves first dementia biomarker test
FDA approves first blood biomarker test for diagnosing dementia Based on the Food and Drug Administration (FDA) September 9, 2025 A groundbreaking milestone in Alzheimer’s research The U.S. Food and Drug Administration (FDA) recently approved the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test, the first biomarker blood test designed to aid in the diagnosis of…
Read More